Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Evaluating the anticancer efficacy of Chara vulgaris ethanolic extract and selenium nanoformulation in Ehrlich carcinoma mice: role of autophagy and apoptosis.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Source:
      Publisher: BioMed Central Country of Publication: England NLM ID: 101088663 Publication Model: Electronic Cited Medium: Internet ISSN: 1472-6750 (Electronic) Linking ISSN: 14726750 NLM ISO Abbreviation: BMC Biotechnol Subsets: MEDLINE
    • Publication Information:
      Original Publication: [London] : BioMed Central, 2001-
    • Subject Terms:
    • Abstract:
      Background: Bioactive compounds with a wide range of chemical compositions and biological functions are found in the Chlorophyceae family. The present work investigated the anticancer effect of ethanolic extract from Chara vulgaris (C. vulgaris) and its selenium nanoformulation (CvSeNPs) against solid Ehrlich carcinoma (SEC).
      Methods: Gas chromatography-mass spectroscopy was used to analyze C. vulgaris, and many analytical methods were used to characterize the biosynthesized CvSeNPs, including zeta potential, particle size, polydispersity index (PDI), SEM, TEM, and FTIR. In addition, mice with SEC were randomly assigned to seven equal groups (n = 6) to investigate possible mechanisms behind the antitumor activity. Group 1: Tumor control, group 2: Tamoxifen (10 mg/kg), group 3: Free SeNPs, group 4: C. vulgaris (25 mg/kg), group 5: C. vulgaris (50 mg/kg), group 6: 25 mg/kg CvSeNPs, group 7: 50 mg/kg CvSeNPs.
      Results: Gas chromatography-mass spectroscopy analysis of the ethanolic extract of C. vulgaris revealed the presence of several bioactive chemicals that may promote anticancer activity. Protein levels of TNF-α, NF-кB, VEGF, and Bcl-2 were suppressed in the CvSeNPs group (50 mg/kg), whereas those of caspase-3, BAX, P53, P62, LC3, and Beclin1 were increased. Additionally, CvSeNPs significantly exceeded similar dosages of free extract in terms of caspase-3, BAX, Bcl-2, P53, TNF-α, NF-кB, VEGF, P62, LC3, and Beclin1 gene expression.
      Conclusion: The CvSeNPs mediated their positive anticancer impact, which manifested as a decrease in tumor volume and an improvement in overall survival rate, by promoting autophagy, apoptosis, and lowering inflammation.
      (© 2025. The Author(s).)
    • Abstract:
      Declarations. Ethics approval and consent to participate: The studies involving animal participants were reviewed and approved by the Research Ethics Committee (Faculty of Pharmacy, Tanta University, Egypt) under approval no. Code of Protocol (TP/RE/3/23 p-0014). Consent for publication: All authors of this study agreed to publish. Institutional review board: The studies involving animal participants were reviewed and approved by the Research Ethics Committee (Faculty of Pharmacy, Tanta University, Egypt) and conformed with the guidelines of the revised Animals (Scientific Procedures) Act 1986 in the UK and Directive 2010/63/EU in Europe, Code of Protocol (TP/RE/3/23 p-0014). Competing interests: The authors declare no competing interests.
    • References:
      ACS Nano. 2016 Nov 22;10(11):9927-9937. (PMID: 27797178)
      Exp Ther Med. 2015 Sep;10(3):863-868. (PMID: 26622406)
      BMC Bioinformatics. 2006 Feb 22;7:85. (PMID: 16504059)
      Mediators Inflamm. 2022 Jan 29;2022:2567150. (PMID: 35132306)
      Toxicol Appl Pharmacol. 2019 Feb 1;364:120-132. (PMID: 30594690)
      Pharmaceuticals (Basel). 2024 Jan 10;17(1):. (PMID: 38256929)
      Nat Plants. 2017 Jul 31;3:17109. (PMID: 28758992)
      FASEB J. 2019 Jul;33(7):8022-8032. (PMID: 30913396)
      Molecules. 2021 Nov 13;26(22):. (PMID: 34833937)
      Mar Drugs. 2015 Sep 30;13(10):6152-209. (PMID: 26437418)
      BMC Complement Med Ther. 2020 Apr 28;20(1):127. (PMID: 32345289)
      Asian Pac J Trop Med. 2011 Mar;4(3):205-11. (PMID: 21771454)
      Infect Immun. 2003 Jan;71(1):465-73. (PMID: 12496197)
      J Am Assoc Lab Anim Sci. 2008 Jan;47(1):11-7. (PMID: 18210992)
      Int J Mol Sci. 2021 Oct 31;22(21):. (PMID: 34769276)
      Int J Med Sci. 2024 Jan 1;21(3):439-453. (PMID: 38250603)
      Integr Cancer Ther. 2020 Jan-Dec;19:1534735420944476. (PMID: 32735464)
      Cancer Sci. 2013 Aug;104(8):1127-34. (PMID: 23679813)
      Int J Pharm Investig. 2013 Jan;3(1):29-41. (PMID: 23799203)
      Mol Biol Rep. 2019 Oct;46(5):4827-4841. (PMID: 31270760)
      Mol Cell Biochem. 2017 Jan;424(1-2):13-33. (PMID: 27696310)
      Food Chem. 2011 Aug 1;127(3):999-1006. (PMID: 25214089)
      Plant Signal Behav. 2011 Sep;6(9):1338-50. (PMID: 21862867)
      J Pineal Res. 2019 Sep;67(2):e12585. (PMID: 31066091)
      Int J Mol Sci. 2021 Nov 24;22(23):. (PMID: 34884496)
      Nanomaterials (Basel). 2023 Jul 29;13(15):. (PMID: 37570523)
      Bioresour Technol. 2014 Jul;163:1-5. (PMID: 24768904)
      Bioinorg Chem Appl. 2021 Nov 27;2021:5985377. (PMID: 34873399)
      Mar Drugs. 2025 Feb 07;23(2):. (PMID: 39997194)
      Trop Parasitol. 2024 Jul-Dec;14(2):84-94. (PMID: 39411680)
      Hum Exp Toxicol. 2014 Sep;33(9):968-79. (PMID: 24347302)
      Front Pharmacol. 2024 Feb 16;15:1345516. (PMID: 38469406)
      Sci Rep. 2021 Nov 24;11(1):22846. (PMID: 34819565)
      Asian Pac J Cancer Prev. 2020 Mar 01;21(3):791-798. (PMID: 32212809)
      Asian Pac J Cancer Prev. ;18(1):239-244. (PMID: 28240526)
      Sci Adv. 2023 Sep 22;9(38):eadj6438. (PMID: 37729407)
      Biochim Biophys Acta. 2009 May;1790(5):283-308. (PMID: 19303911)
      Chem Soc Rev. 2013 Dec 7;42(23):8870-94. (PMID: 24030774)
      Colloids Surf B Biointerfaces. 2018 Oct 1;170:280-292. (PMID: 29936381)
      Biomed Pharmacother. 2019 Mar;111:42-50. (PMID: 30576933)
      Braz J Biol. 2022 Jan 21;82:e256927. (PMID: 35081252)
      ILAR J. 2021 Dec 31;62(1-2):238-273. (PMID: 34180990)
      Antioxidants (Basel). 2022 Sep 30;11(10):. (PMID: 36290687)
      Int J Biol Macromol. 2023 Mar 31;232:123261. (PMID: 36649870)
      Front Mol Biosci. 2023 Apr 12;10:1120422. (PMID: 37122561)
      Pharmaceutics. 2022 Apr 16;14(4):. (PMID: 35456709)
      J Int Med Res. 2020 Dec;48(12):300060520971422. (PMID: 33322998)
      Biomed Pharmacother. 2019 Mar;111:802-812. (PMID: 30616079)
    • Contributed Indexing:
      Keywords: Chlorophyceae; Antitumor; Micro-algae; Selenium nanoparticles; Solid Ehrlich carcinoma
    • Accession Number:
      0 (Plant Extracts)
      H6241UJ22B (Selenium)
      3K9958V90M (Ethanol)
      0 (Antineoplastic Agents)
    • Publication Date:
      Date Created: 20250702 Date Completed: 20250702 Latest Revision: 20250704
    • Publication Date:
      20260130
    • Accession Number:
      PMC12211136
    • Accession Number:
      10.1186/s12896-025-00998-y
    • Accession Number:
      40597910